Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Category: Uncategorized

Pentoxifylline

Plain-language summaryIntrigue 42 / 100

Pentoxifylline (Trental) is a methylxanthine, structurally related to caffeine and theophylline, approved in 1984 for intermittent claudication (leg pain from peripheral artery disease while walking). Mechanism is weak, non-selective inhibition of phosphodiesterases (PDE3, 4, 5), but the practically meaningful effect is making red blood cells more deformable and reducing platelet aggregation, improving microcirculatory blood flow through narrowed vessels. Off-label exploration includes alcoholic hepatitis, vascular dementia, and tinnitus, with mixed results. The clinical effect in claudication is real but modest, and exercise therapy and surgical revascularization have largely overtaken it. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

38/100

A 1984 approved hemorheologic workhorse with modest effects and limited modern research pull

Look, pentoxifylline is about as 1984 as it gets. Trental, Hoechst chemistry, methylxanthine scaffold. It inhibits PDE3, PDE4, and PDE5 with weak non-selective affinity, which raises intracellular cAMP and cGMP, and the net effect that made it commercially viable was improved erythrocyte deformability. Red blood cells that squeeze better through narrowed peripheral vasculature. That was enough to get an FDA approval for intermittent claudication and it sat there, quietly, for forty years.

The mechanism story is actually more layered than the initial approval suggested. Beyond hemorheology, pentoxifylline suppresses TNF-alpha production and has a modest anti-inflammatory footprint that generated off-label interest in cerebrovascular small-vessel disease, tinnitus, radiation fibrosis (the pentoxifylline plus tocopherol protocol has real data there), and more recently COVID-19 microvascular injury. There’s also a thread of hepatology literature exploring its anti-fibrotic properties via PDE4 inhibition. None of that is novel in 2026, but it does mean the compound isn’t purely a one-trick hemorheologic artifact. We give it credit for the multi-axis mechanism even if none of the axes are particularly fresh.

The differentiation problem is real. In the PDE inhibitor space, pentoxifylline is weak and non-selective, which makes it useful only where you specifically want weak and non-selective. PDE4 selectivity? Roflumilast is miles ahead. PDE5 selectivity? Sildenafil and tadalafil make pentoxifylline look like noise. As a hemorheologic reference compound it’s essentially the only approved agent in that category, which gives it a narrow differentiation moat, but that moat sits in a field most investigators aren’t actively farming.

Evidence quality is the strongest axis here, purely because it’s an approved drug with decades of trial data. Cochrane reviews of the intermittent claudication indication are real, and the effect size is modest but measurable. The radiation fibrosis protocol is one of the better-supported off-label applications we’ve seen in this class. But thats a ceiling, not a floor. The trial base is old, replication happened years ago, and what we’re left with is a well-characterized compound with no particularly exciting frontier.

Honestly, the main research utility in 2026 is as a reference probe. If you’re studying microvascular dynamics, erythrocyte mechanics, or weak pan-PDE biology and you need a pharmacologic anchor with an established safety profile and predictable behavior, pentoxifylline earns a place in the toolkit. It’s not the compound you build a program around. It’s the compound you use to establish a baseline while you test something more interesting alongside it.

Novelty

18

Mechanism promise

30

In-category differentiation

35

Evidence quality

62

Translational signal

52

Research bench value

42

Rationale Pentoxifylline scores low on novelty because it’s a four-decade-old FDA approval whose core mechanism (weak non-selective PDE inhibition plus erythrocyte deformability improvement) has been thoroughly characterized for decades; it retains modest bench utility as a reference hemorheologic probe but is clearly outclassed in the PDE inhibitor space by more selective agents and carries only modest translational signal even in its approved indication.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Methylxanthine PDE inhibitor / hemorheologic agent

A methylxanthine non-selective phosphodiesterase inhibitor that improves erythrocyte deformability and microcirculation; used for intermittent claudication.

Abstract

Pentoxifylline (1-(5-oxohexyl)-3,7-dimethylxanthine; CAS 6493-05-6; molecular formula C13H18N4O3; molecular weight 278.31) is a methylxanthine non-selective phosphodiesterase inhibitor developed at Hoechst (now Sanofi) and approved by the FDA in 1984 under the trade name Trental. Mechanism: weak non-selective PDE inhibition (PDE3, PDE4, PDE5) increases intracellular cAMP and cGMP. The principal clinically meaningful effect is improvement in erythrocyte deformability and reduced platelet aggregation, producing improved microcirculatory blood flow. Approved for intermittent claudication. Off-label use in chronic cognitive impairment from small-vessel cerebrovascular disease, peripheral neuropathy, and tinnitus. Plasma half-life is approximately 0.4 to 0.8 hours; metabolism is hepatic. Used as a reference hemorheologic agent and weak non-selective PDE inhibitor.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-310Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Oleoylethanolamide (OEA)

Our opinion on this compoundEstablished, active research

50/100

Canonical PPAR-alpha satiety probe with solid multi-lab rodent evidence but stalled clinical translation

Look, OEA is the kind of compound that earns its place in a research library for one specific reason: it’s the canonical probe for PPAR-alpha mediated satiety biology, and thats a real and underexplored axis. The Rodriguez de Fonseca group’s 2001 Nature paper established the basic story – small intestine synthesizes OEA in response to dietary fat, it binds PPAR-alpha with about 40 nM affinity, and signals fullness to the brain primarily through vagal afferents. That mechanism is genuinely distinct from leptin, ghrelin, and the peptide YY axis. If you’re investigating gut-brain satiety crosstalk and want a tool that isn’t just another CCK surrogate, OEA is the compound you reach for.

The rodent evidence base is solid and multi-lab. The mechanism is well-replicated across feeding behavior, lipid metabolism, and gut motility endpoints. Where OEA gets complicated is human translation – FAAH clears it fast enough that pharmacological administration of native OEA is a real pharmacokinetic problem. The short half-life isn’t fatal for bench work (you can probe endpoints in vitro and in acute animal models without worrying about trough levels), but it explains why clinical development stalled. Small human studies on OEA-based supplementation exist, but they haven’t produced the effect sizes that would move this into a different scoring tier.

What we like here is the mechanistic specificity. PPAR-alpha satiety signaling is genuinely separate from the GLP-1/GIP axis dominating metabolic pharmacology right now, and how these pathways interact is an active research question. OEA gives you a clean tool to probe the fatty acid-sensing arm of intestinal satiety signaling. That’s real value for anyone building experiments around feeding behavior or metabolic flexibility. The endocannabinoid-adjacent chemistry also makes it useful for investigating cross-talk with the AEA/CB1 axis without the receptor-binding confounds that come with direct cannabinoid tools.

What we dont love is that the novelty premium has worn off. The core mechanism has been known for over two decades. Clinical translation is hampered by PK, and nobody has solved that problem elegantly. OEA-content supplements are widely available commercially, which is a sourcing positive but also a clear signal that you’re not at the frontier anymore. It’s a mature, mechanistically interesting endogenous lipid mediator. For investigators focused on energy homeostasis, gut-brain axis signaling, or PPAR-alpha biology specifically, OEA earns its shelf space as the reference standard. Outside that specific program, it’s a second-tier priority.

Novelty

40

Mechanism promise

55

In-category differentiation

58

Evidence quality

50

Translational signal

38

Research bench value

65

Rationale OEA scores well on bench value as the reference probe for PPAR-alpha mediated gut-brain satiety signaling, but novelty is low after two decades of literature (mechanism characterized 2001), clinical translation is complicated by rapid FAAH-mediated clearance, and the compound occupies a well-defined niche rather than opening new territory.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Endogenous N-acylethanolamide (PPAR-alpha satiety signal)

An endogenous N-acylethanolamide; a PPAR-alpha agonist that signals satiety from the small intestine after fatty meals.

Abstract

Oleoylethanolamide (OEA; CAS 111-58-0; molecular formula C20H39NO2; molecular weight 325.53) is an endogenous N-acylethanolamide synthesized in the small intestine in response to dietary fat. The compound binds PPAR-alpha (Ki approximately 40 nM) with full agonist activity and signals satiety to the brain via vagal afferents and through direct CNS PPAR-alpha activation. The mechanism is distinct from leptin and ghrelin and represents a separate satiety pathway tied directly to fat intake. Pharmacological administration in rodents reduces food intake and body weight; clinical translation has been complicated by the short half-life (FAAH-mediated degradation). Used as the canonical PPAR-alpha satiety signal in metabolic and feeding research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-326Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Bufotenin

Plain-language summaryIntrigue 44 / 100

Bufotenin is the 5-hydroxyl version of N,N-DMT, found in Anadenanthera seeds (used for the South American snuffs yopo and cohoba) and in Bufo amphibian secretions. The hydroxyl group hurts blood-brain barrier penetration, so peripheral serotonin-like effects (vasoconstriction, nausea, sweating) tend to dominate any central activity. Whether bufotenin produces a meaningful psychedelic experience by typical routes is contested in the literature, with intramuscular and pulmonary routes producing variable reports. The compound is important historically and ethnobotanically but is rarely used in modern psychedelic research because of the awkward pharmacokinetic profile. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

35/100

A structural curiosity with real SAR probe value but weak evidence and negligible translational path

Look, bufotenin is one of those compounds that tells you more about other compounds than it does about itself. The whole point of 5-HO-DMT in a serious research context isn’t that it’s going to become a drug or even a useful therapeutic probe in its own right. It’s that the 5-hydroxy group is exactly what you reach for when you want to understand what that modification does to a tryptamine. Compared to N,N-DMT, it has substantially poorer blood-brain barrier penetration because the 5-OH group increases polarity and reduces central distribution. That’s the mechanism story, and honestly, it’s a useful story for structure-activity work even if it’s not exciting in isolation.

The pharmacology shifts toward peripheral 5-HT receptor effects: cardiovascular, sympathomimetic. That distinction between central psychedelic activity and peripheral serotonergic signaling is genuinely relevant to anyone doing tryptamine SAR, and bufotenin is the reference comparator you use to make that case. We like that it’s a clean chemical tool in that narrow context. What we don’t like is that the human data is essentially uninterpretable. The 1950s and 1960s studies, Fabing and Hawkins’ original 1956 prison-population work included, are so confounded by route of administration, dose uncertainty, and cardiovascular toxicity signals that its psychoactivity in humans remains an open and mostly uninteresting question. Whether the compound produces central effects or whether the reported effects were largely peripheral and toxic is still not resolved cleanly, and thats not a gap that’s attracting serious modern funding.

The 5-HT2A agonism is well-defined in vitro. The binding affinity is real and the molecular target is not in dispute. But in the tryptamine space right now, the serious research energy is going toward psilocybin, DMT, and next-generation psychoplastogens with neuroplasticity signals. Bufotenin isn’t part of that conversation. It’s Schedule I in the US, which limits what you can do with it, and it hasn’t generated a clinical-stage program anywhere that we can find. The compound is essentially a historical reference and a SAR anchor.

For a tryptamine lab running comparative pharmacology, bufotenin has real but narrow utility. You’d use it to make the case about the 5-OH modification’s effects on CNS penetration and receptor selectivity profile. Outside of that specific application, the evidence is too old, too methodologically weak, and too peripheral-focused to generate research excitement. Bench value is solid in its lane. Everything else is mediocre to poor. That’s what a 35 looks like.

Novelty

35

Mechanism promise

38

In-category differentiation

42

Evidence quality

25

Translational signal

20

Research bench value

50

Rationale Bufotenin sits at an awkward intersection: it’s chemically informative as a tryptamine comparator (the 5-OH group is exactly what you study to understand BBB penetration and peripheral vs. central 5-HT2A effects), but the human evidence base is a mess of confounded 1950s trials and the compound has generated no serious clinical interest. Schedule I cap at 65 doesn’t bind because the raw score is already 35.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Tryptamine / 5-HT2A agonist

5-hydroxy-N,N-dimethyltryptamine; a tryptamine related to DMT and serotonin; found in Anadenanthera seeds and toad secretions.

Abstract

Bufotenin (5-hydroxy-N,N-dimethyltryptamine, 5-HO-DMT; CAS 487-93-4; molecular formula C12H16N2O; molecular weight 204.27) is a tryptamine isolated from Anadenanthera seeds (used for South American snuffs called yopo and cohoba) and from Bufo amphibian secretions. Structurally bufotenin is the 5-hydroxy analog of N,N-DMT and the N,N-dimethyl analog of serotonin. Pharmacology: 5-HT2A agonism with poor blood-brain barrier penetration owing to the polar 5-hydroxy group; the central versus peripheral effect ratio is shifted toward peripheral 5-HT effects (cardiovascular, sympathetic) compared to DMT. The compound’s psychoactivity in humans has been debated for decades, with some 1950s and 1960s studies reporting psychotic-like effects (confounded by toxicity) and other studies suggesting limited central activity. Schedule I in the US. Used as a research probe for 5-HT2A pharmacology and as a comparator to DMT in tryptamine structure-activity studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-342Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Bimagrumab

Plain-language summaryIntrigue 64 / 100

Bimagrumab is a humanized antibody against the activin receptor type II (the receptor that myostatin and related ligands bind) developed by Novartis and MorphoSys. By blocking the receptor at the cell surface, it prevents engagement by myostatin, activin A, and GDF-11 in one shot. It has been investigated for sporadic inclusion body myositis, sarcopenia, and (more recently) obesity-related muscle preservation, where it has produced meaningful fat loss alongside muscle gain in early trials. Most trials have not met primary endpoints in muscle disease populations, but the obesity application has revived clinical interest. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNovel, promising

65/100

Receptor-level ActRII blocker with an unusual fat-loss plus muscle-gain profile that stands apart in the GLP-1 era

Look, the myostatin inhibitor space has a graveyard in it. ACE-031 was stopped for safety. Stamulumab showed muscle signal in Becker but couldnt replicate it cleanly. The whole class got written off by a lot of investigators around 2015. Bimagrumab is the compound that survived that shakeout, and the reason it survived is that it’s doing something structurally different from its predecessors.

Most myostatin pathway inhibitors are ligand traps or single-ligand antibodies. Bimagrumab binds ActRIIA and ActRIIB directly at the receptor level, which means it blocks myostatin, activin A, and GDF-11 in one shot. That’s not a marginal technical distinction. Activin A in particular is now understood to be a co-driver of muscle wasting in several contexts, and blocking it alongside myostatin gives a broader suppression of the pathway than a selective antibody can achieve. That’s the mechanism we find genuinely interesting here.

The RESILIENT trial in sporadic inclusion body myositis showed lean mass gains. The sarcopenia work showed lean mass gains. Those are real, replicated signals in two different wasting contexts. But the thing that really sharpened our interest is the 2020 BIM-T2D phase 2 data, where bimagrumab produced roughly 21 percent fat mass reduction alongside muscle preservation in obese patients with type 2 diabetes. That combination profile is unusual. Most pharmacological interventions that drive fat loss also drive some lean mass loss. Bimagrumab’s direction of effect is inverted on the muscle side, and that matters enormously now that GLP-1 agonists are being criticized for the lean mass loss they produce during rapid weight reduction.

Honestly, the timing here matters as much as the mechanism. If this data had come out in 2014 it would have been interesting but not urgent. Coming out in 2020 and being developed further in parallel with semaglutide and tirzepatide’s rise, the muscle-preserving fat loss profile is suddenly one of the more clinically relevant compound profiles in the space. Novartis has continued development, and there are combination-with-GLP-1 trials being discussed or initiated.

What we dont like: the evidence base is still mostly phase 2. The fat mass reduction finding needs phase 3 confirmation. And the underlying ActRII biology, while elegant, is not fully de-risked. Off-target effects on reproductive biology and bone are a real pharmacology concern at this receptor level. As a research probe for receptor-level myostatin pathway biology, it’s genuinely the cleanest tool available. As a compound, its overall profile is strong enough to warrant serious attention but not yet the finished story.

Novelty

62

Mechanism promise

73

In-category differentiation

65

Evidence quality

60

Translational signal

65

Research bench value

60

Rationale Bimagrumab scores well on mechanism and differentiation because its ActRII receptor-level blockade is mechanistically distinct from failed ligand traps and selective myostatin antibodies, and the 2020 BIM-T2D phase 2 data showing ~21% fat mass reduction with concurrent lean mass gain is genuinely unusual. Novelty is held down somewhat because the compound has been in clinical development since roughly 2013; the obesity angle is fresh but the underlying biology is a decade old.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Anti-activin receptor type II monoclonal antibody

A humanized monoclonal antibody against activin receptor type II; investigated for sarcopenia, sIBM, and obesity-related muscle preservation.

Abstract

Bimagrumab (BYM338; humanized IgG1 monoclonal antibody; molecular weight approximately 145 kDa) is a humanized monoclonal antibody against activin receptor type II (ActRII), developed at MorphoSys and Novartis. The compound binds ActRIIA and ActRIIB receptors on the cell surface, blocking access by myostatin, activin A, and GDF-11; the receptor-level blockade is mechanistically distinct from ligand traps (ACE-031) and from selective myostatin antibodies (stamulumab). Phase 2 trials in sporadic inclusion body myositis (RESILIENT) and sarcopenia demonstrated muscle mass increases. The compound generated substantial interest in 2020 after a phase 2 trial in obesity with type 2 diabetes (BIM-T2D) showed approximately 21 percent reduction in fat mass with concurrent muscle preservation, an unusual profile that has subsequently driven obesity-related development. Used as a research probe for receptor-level myostatin pathway inhibition.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-359Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Sarcosine

Plain-language summaryIntrigue 60 / 100

Sarcosine is an N-methylated version of the amino acid glycine, made naturally in your body. It blocks the GlyT1 transporter that normally clears glycine from the synapse, so glycine builds up near NMDA receptors and boosts their function (glycine is the other co-agonist alongside D-serine). This is essentially a back-door way to enhance NMDA signaling without giving D-serine directly. Phase 2 trials added it to standard antipsychotics in schizophrenia and to antidepressants in depression, with small to moderate effects on negative symptoms and mood. Bitopertin, a more potent selective GlyT1 inhibitor, ran the same play but failed phase 3, which tempered enthusiasm for the whole approach. Reference compound for glycine-transporter pharmacology. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

49/100

Canonical GlyT1 research probe with real phase 2 data, but bitopertin’s failure shadows the class

Look, sarcosine has a legitimately interesting story. N-methylglycine acts as a competitive substrate at GlyT1, blocking glycine reuptake and raising extracellular glycine near NMDA receptors. The glycine co-agonist site is a real pharmacological target, distinct from the glutamate site and from direct agonism, and for investigators studying NMDA hypofunction biology this is the relevant mechanism. Sarcosine complements D-serine administration as a different route to the same destination: more glycinergic tone at NMDA receptors without direct receptor activation.

The clinical story is mixed but not empty. Phase 2 adjunct trials in schizophrenia, primarily alongside risperidone and olanzapine, produced small-to-moderate improvements in negative symptoms. That’s worth noting because negative symptoms are the piece of schizophrenia that antipsychotics basically dont touch. A separate phase 2 signal in MDD exists too, though thinner. Effect sizes are real and statistically meaningful in several trials; multi-lab replication exists. No phase 3 has been run for sarcosine itself, which limits how far the evidence can carry you.

Here’s what weighs heavily against it: bitopertin. RG1678 was the field’s best attempt to turn potent, selective GlyT1 inhibition into an approved drug, and it failed three phase 3 trials in schizophrenia negative symptoms. That failure doesn’t indict sarcosine’s bench utility, but it does cast a long shadow over GlyT1 as a therapeutic pivot. Either the NMDA hypofunction theory doesn’t translate the way the preclinical mechanism predicts, or the effect size ceiling is too low to clear phase 3, or both. Investigators building a program around this axis need to reckon with that history before committing resources.

What sarcosine does well is its probe role. It remains the canonical tool for GlyT1 substrate inhibition studies, indexed across decades of mechanistic literature. If you’re characterizing NMDA co-agonist site pharmacology, measuring glycine spillover kinetics, or interrogating GlyT1 transporter behavior in a CNS model, sarcosine is accessible, well-characterized, and genuinely useful. Thats real bench value, even if its not frontier value.

We think the right framing is: sarcosine is a solid niche probe for a defined research program with a modest but real clinical signal that’s already been tested hard by drug development. The mechanism isn’t new, the bitopertin data tells you something about the ceiling, and the novelty story stopped compounding years ago. Score reflects that. Useful for investigators already operating in NMDA co-agonist or GlyT1 biology; not a reason to start a new program from scratch in 2026.

Novelty

38

Mechanism promise

55

In-category differentiation

50

Evidence quality

50

Translational signal

45

Research bench value

65

Rationale Sarcosine earns its score on genuine bench probe utility and multi-lab phase 2 clinical data across schizophrenia and MDD, but the mechanism is established not novel, and bitopertin’s consecutive phase 3 failures between 2013-2016 put a hard ceiling on enthusiasm for the GlyT1 therapeutic angle. No amino acid cap applies: GlyT1 transporter pharmacology distinguishes sarcosine clearly from plain glycine, analogous to how sulbutiamine differs from thiamine.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Glycine reuptake inhibitor (GlyT1)

N-methylglycine; an endogenous methylglycine that inhibits glycine reuptake at GlyT1, elevating synaptic glycine.

Abstract

Sarcosine (N-methylglycine; CAS 107-97-1; molecular formula C3H7NO2; molecular weight 89.09) is an endogenous N-methylated derivative of glycine and a competitive substrate of the glycine transporter type 1 (GlyT1). Pharmacologically, sarcosine inhibits glycine reuptake at GlyT1, elevating extracellular glycine concentrations near NMDA receptors and consequently enhancing NMDA receptor function via the glycine co-agonist site. The mechanism complements direct D-serine administration. Phase 2 trials in schizophrenia (as adjunct to risperidone or olanzapine) and major depressive disorder have shown small to moderate effects on negative symptoms and depressive symptoms. Plasma half-life is approximately 7 hours; the compound is well tolerated. The selective GlyT1 inhibitor bitopertin (RG1678) was developed as a more potent alternative but failed phase 3 trials. Used as the canonical GlyT1 substrate inhibitor in NMDA receptor research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-375Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Boldenone

Plain-language summaryIntrigue 42 / 100

Boldenone is essentially testosterone with an added double bond between carbons 1 and 2. Originally approved in 1949 as a human drug at Ciba (Parenabol, withdrawn) and later developed for veterinary use as Equipoise, the name still associated with it. The 1,2 double bond makes the molecule a poorer substrate for aromatase, so it converts to estrogen at roughly half the rate of testosterone at equivalent doses, the main practical feature distinguishing it. The undecylenate ester gives the injectable formulation a long half-life around 14 days. Schedule III in the US under the AAS Control Act despite never having current human medical approval. Reference low-aromatizing testosterone analog in steroid pharmacology research. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

24/100

Old veterinary AAS with narrow reference-probe utility and stagnant research trajectory

Boldenone is a 75-year-old compound. That’s the core of the story here. Ciba introduced it in 1949 as Parenabol for human use, pulled it, and it found its permanent home as Equipoise in veterinary practice. The research conversation around it has been essentially stagnant for decades; theres no active clinical development program, no IND, no therapeutic application on the horizon. For a library built around the frontier, boldenone is not there.

The mechanism is straightforward: androgen receptor agonism with the 1,2 double bond reducing aromatase substrate quality to roughly half that of testosterone. That’s the single pharmacological hook distinguishing boldenone from plain testosterone, and while it’s a real and measurable difference, it’s not a novel mechanism. It’s a structural variation on one of the most thoroughly studied receptor systems in endocrinology. Single-receptor agonism in a class that has dozens of characterized analogs doesn’t score high on mechanism promise, and boldenone doesn’t earn any points for mechanism elegance beyond that one structural tweak.

Where boldenone has some legitimate research value is as a reference compound. If you’re running in vitro or in vivo androgen biology work and you want to separate androgenic effects from estrogenic confounds without layering in an aromatase inhibitor, boldenone offers a cleaner experimental model. The erythropoietic effects have been studied, and the compound has shown up as a comparator in androgen receptor binding assays. That’s real bench utility, if narrow. We think the reference-probe angle is the only serious argument for keeping it in a research inventory.

The evidence base is a genuine problem. Most of what exists is pharmacokinetic characterization covering ester hydrolysis rates and detection windows for anti-doping work, plus veterinary pharmacology. Human clinical data is essentially observational, drawn from illicit use contexts rather than controlled trials. Replication across independent research groups for any specific effect claim is limited. Dont have the multi-lab, methodologically sound preclinical base you’d want before calling something a serious target.

Honestly, the main reason boldenone appears in a library like this is category completeness and its historical role as a reference AAS. For an investigator studying reduced-aromatization androgen biology, there are more accessible and better-characterized options: testosterone plus a well-characterized aromatase inhibitor gives more experimental control, and nandrolone carries actual clinical literature. We’d deprioritize boldenone for almost any active research program. The narrow reference-probe case keeps it off the floor, but old mechanism, thin controlled evidence, Schedule III friction, and a stagnant pipeline put it well down the priority list.

Novelty

18

Mechanism promise

20

In-category differentiation

25

Evidence quality

22

Translational signal

28

Research bench value

38

Rationale Boldenone scores low across novelty and mechanism because it’s a 75-year-old AR agonist variant with no active clinical program and a saturated-class mechanism; bench value is slightly elevated for its narrow use as a low-aromatizing reference probe, but the combination of thin controlled evidence and stagnant literature keeps the overall well below the Schedule III cap of 75.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Testosterone analog (1-dehydro testosterone)

A 1-dehydro testosterone analog; an injectable AAS originally developed for veterinary use, widely diverted to human non-medical use.

Abstract

Boldenone (17-beta-hydroxyandrosta-1,4-dien-3-one; CAS 846-48-0; molecular formula C19H26O2; molecular weight 286.41) is a 1-dehydro testosterone analog originally developed at Ciba and approved by the FDA in 1949 (Parenabol, withdrawn) and subsequently developed for veterinary use as Equipoise (the brand most associated with the compound). The 1,2 double bond reduces aromatase substrate quality, producing approximately 50 percent the estrogen conversion of testosterone at equivalent doses; this is the principal pharmacological feature distinguishing boldenone from testosterone. The undecylenate ester (Equipoise) provides a long half-life (approximately 14 days) for veterinary or non-medical injectable use. Schedule III in the US (covered by the AAS Control Act despite no human medical approval). Plasma half-life of native boldenone is short; ester formulations release over weeks. Used as a reference low-aromatizing testosterone analog in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-391Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Modafinil

Plain-language summaryIntrigue 80 / 100

Modafinil is the world’s most prescribed wakefulness-promoting medication, sold as Provigil. It is FDA-approved for narcolepsy and shift work disorder. Off-label use for fatigue and cognitive enhancement is widespread. The mechanism involves dopamine transporter binding plus downstream histamine and orexin activation. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundFederally scheduled

60/100

Approved Schedule IV eugeroic with a genuinely contested mechanism that keeps it more alive as a research probe than its age suggests

Look, modafinil is interesting in the specific way a 25-year-old approved drug can still be interesting: the mechanism is genuinely not fully settled, and that keeps it more alive as a research object than its history would suggest.

The DAT inhibition story is real, but the affinity numbers tell a strange tale. A Ki around 4 microM is surprisingly weak for the magnitude of wakefulness effect you see clinically. That gap is what keeps researchers digging. The downstream orexinergic cascade, histamine elevation in the tuberomammillary nucleus, glutamatergic bias in the prefrontal cortex: these are all real pharmacological events, but the primary trigger is still debated. Some groups argue NET inhibition contributes more than the DAT story acknowledges. Others point to non-transporter targets entirely. Thats not a knock on modafinil; its actually the source of its continued bench value as a probe for wakefulness circuitry rather than a clean single-receptor tool.

The differentiation score reflects that modafinil defines its category. The profile is genuinely distinct from amphetamines: no steep dopamine release kinetics, no meaningful peripheral sympathomimetic load at typical research concentrations, softer abuse liability. Armodafinil, the R-enantiomer, is the cleaner modern form and increasingly preferred in new programs, but modafinil as the racemic parent is better represented in the existing literature and remains the standard comparator for the eugeroic class.

Evidence quality is one of modafinil’s stronger suits, and honestly the most straightforward thing about it. Multiple well-controlled RCTs in narcolepsy and shift work disorder, FDA approval going back to 1998, decades of follow-on mechanistic work across independent groups. The weak link is the cognitive enhancement literature in healthy subjects, where effect sizes are small and replication is inconsistent. If your research question touches a diagnosed wakefulness disorder, the evidence base is mature and usable. If you’re studying it as a general cognitive enhancer in healthy populations, the numbers will disappoint you.

From a pure bench perspective, modafinil has real value as a pharmacological probe for DAT-adjacent circuitry and orexin biology. The low affinity and complex selectivity profile that make it mechanistically murky are precisely what make it useful for studying network-level wakefulness rather than receptor-level dissections. Investigators working on shift work physiology, fatigue models, or orexin-deficient animal preparations reach for it as a reference compound.

We rate it 60. The Schedule IV ceiling sits at 75 but doesn’t bind here; modafinil earns this position on its own terms. It’s a well-characterized, genuinely useful research compound held back by age, modest and inconsistent off-label effect sizes, and the fact that armodafinil has largely eclipsed it in new program design.

Novelty

28

Mechanism promise

62

In-category differentiation

65

Evidence quality

78

Translational signal

72

Research bench value

65

Rationale Modafinil scores on the strength of its multi-target wakefulness mechanism, a strong clinical evidence base in approved indications, and real bench utility as a DAT/orexin probe; novelty is dragged down by 25 years of literature and armodafinil’s encroachment. The Schedule IV cap of 75 does not bind; a natural score of 60 reflects a well-characterized but aging compound whose mechanism debate is the most interesting thing about it.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Eugeroic / wakefulness-promoting agent

A benzhydryl sulfinyl acetamide approved for narcolepsy and shift work disorder, characterized by selective dopamine transporter binding and downstream histaminergic activation.

Abstract

Modafinil (CAS 68693-11-8; molecular formula C15H15NO2S; molecular weight 273.35) is a wakefulness-promoting agent first synthesized at Laboratoire Lafon in France in the 1970s as the active metabolite of adrafinil and approved by the FDA in 1998 for excessive daytime sleepiness associated with narcolepsy, shift work sleep disorder, and obstructive sleep apnea. The compound is a racemic mixture; the (R)-enantiomer (armodafinil) carries the majority of the wakefulness-promoting activity and is marketed separately. The principal mechanism is binding to the dopamine transporter (DAT) with weak inhibitor affinity (Ki approximately 4 microM), producing modest extracellular dopamine elevation in the striatum and prefrontal cortex without the steep release kinetics characteristic of amphetamines or methylphenidate. Downstream effects include activation of orexinergic neurons in the lateral hypothalamus, elevation of histamine in the tuberomammillary nucleus, and increased glutamatergic tone in the prefrontal cortex with concurrent attenuation of GABAergic inhibition. The plasma half-life is 12 to 15 hours; oral bioavailability is high (greater than 80 percent); metabolism is hepatic via CYP3A4 and to a lesser extent via amide hydrolysis. Clinical efficacy in narcolepsy and shift work indications is well established; off-label use for cognitive enhancement in healthy individuals is widespread but the magnitude of cognitive benefit in healthy subjects is small and inconsistent across trials. Schedule IV in the United States. Common adverse events include headache, nausea, anxiety, and insomnia; rare serious events include Stevens-Johnson syndrome and DRESS. The compound is not a controlled substance under international treaty but is regulated nationally in most jurisdictions.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-016Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Levetiracetam

Plain-language summaryIntrigue 78 / 100

Levetiracetam, sold as Keppra, is a piracetam-derived anticonvulsant approved by the FDA. Unlike older racetams, it works through the SV2A synaptic vesicle protein rather than glutamate receptors. It is one of the most prescribed anticonvulsants. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

51/100

Mature SV2A antiepileptic with a genuinely interesting but still-inconclusive hippocampal-hyperactivity cognitive angle

Look, levetiracetam is an odd compound to evaluate for a research library. On one hand, it’s a twenty-five-year-old FDA-approved antiepileptic that every neuroscience trainee has heard of. On the other hand, the SV2A binding story that defines it is genuinely distinct from anything else in the pyrrolidinone class, and the off-label cognitive application it’s attracted over the last decade is actually interesting in ways the epilepsy literature alone doesn’t capture.

The mechanism is the main reason we give it serious consideration. Classical racetams have notoriously murky pharmacology. Levetiracetam doesn’t play that game. It binds SV2A, a presynaptic vesicle membrane protein, with meaningful affinity (Kd around 1 micromolar), and that interaction appears to modulate calcium-dependent neurotransmitter release rather than touching the usual GABA or glutamate receptor targets directly. That’s a real mechanism, cleanly defined, and it makes the compound a genuinely useful probe for synaptic vesicle biology in ways that most nootropic-adjacent molecules simply aren’t.

The more interesting research story, though, is the hippocampal hyperactivity hypothesis. There’s a coherent mechanistic argument, championed most visibly by work out of Li-Huei Tsai’s group at MIT and echoed by others, that pathological hippocampal hyperactivity in early Alzheimer’s and mild cognitive impairment is causally upstream of some of the cognitive deficit. The prediction: low-dose levetiracetam should attenuate that hyperactivity and produce measurable cognitive benefit. Small trials have reported positive signals. The problem is that larger follow-up work has come back messier, and the field hasn’t landed on a clean answer. We dont have a definitive multi-site RCT confirming the MCI application. Thats the gap that’s keeping this from scoring higher.

As a bench tool, it’s solid. If you’re running hippocampal network studies, probing SV2A biology, or trying to model focal synchrony, levetiracetam is a well-characterized pharmacological lever with established analytical reference standards and straightforward sourcing. That’s a real practical advantage over more exotic peptides.

What we don’t like: the MCI cognitive enhancement angle has been promising for years but keeps returning ambiguous results. The translational arrow is undeniably strong for epilepsy, but for the application that makes this interesting to a research-library audience, the evidence is still unresolved. That’s not a knock on the compound’s biology, it may well be a real and reproducible effect, but it means you’re investing in a hypothesis rather than a validated mechanism. Worth having in scope if hippocampal network biology is part of your program; hard to justify otherwise.

Novelty

30

Mechanism promise

52

In-category differentiation

45

Evidence quality

70

Translational signal

62

Research bench value

55

Rationale Levetiracetam scores modestly on novelty (approved 1999, well-catalogued) but earns real points on mechanism and bench value: SV2A binding is cleanly defined and distinct from classical racetam pharmacology, making it a genuine probe for synaptic vesicle biology and hippocampal network research. The off-label MCI/hippocampal-hyperactivity angle drives interest but the clinical evidence remains frustratingly mixed, keeping translational scores mid-range.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

S-enantiomer pyrrolidinone (SV2A ligand)

The (S)-enantiomer of etiracetam, FDA-approved as Keppra for partial-onset seizures, characterized by the SV2A synaptic vesicle binding mechanism distinct from classical racetam pharmacology.

Abstract

Levetiracetam (Keppra; (S)-α-ethyl-2-oxo-1-pyrrolidineacetamide; CAS 102767-28-2; molecular formula C8H14N2O2; molecular weight 170.21) is the (S)-enantiomer of etiracetam, developed at UCB Pharma and approved by the FDA in 1999 for partial-onset seizures, with subsequent expansion to primary generalized tonic-clonic seizures and myoclonic seizures. The compound is distinct from other racetams in mechanism: levetiracetam binds with high affinity (Kd approximately 1 microM) to synaptic vesicle protein 2A (SV2A), a presynaptic vesicle membrane protein involved in neurotransmitter release regulation. SV2A binding modulates calcium-dependent neurotransmitter release and reduces hypersynchronous neuronal firing in epileptic networks. The compound has minimal effect on classical neurotransmitter receptors. Pharmacokinetics: plasma half-life 6 to 8 hours; oral bioavailability essentially complete; renal excretion with minimal hepatic metabolism. Approved doses are 1000 to 3000 mg per day in two divided administrations. The compound is also studied off-label for cognitive enhancement based on hippocampal hyperactivity attenuation, with mixed results in mild cognitive impairment trials. Schedule status varies; the compound is not scheduled federally in the United States but is prescription-only.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-033Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Phenibut

Plain-language summaryIntrigue 60 / 100

Phenibut is a Russian anxiolytic that activates GABA-B receptors (the same receptors as the prescription drug baclofen). It produces anxiolysis at low doses but carries dependence and severe withdrawal risk with regular use. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

29/100

Soviet-era GABA-B agonist with real anxiolytic signal but low novelty, dependence risk, and no Western trial base

Look, phenibut is a compound that’s been around since Khrushchev was in power, and that history cuts both ways. The 4-amino-3-phenylbutanoic acid structure is clever for its time: slap a phenyl group on GABA and suddenly you’ve got BBB penetration that GABA itself can’t achieve. That was genuinely interesting in 1964. It’s less interesting now.

The mechanism is GABA-B agonism, which puts it squarely in baclofen territory. Baclofen is the reference GABA-B agonist, well-characterized, cheap, and carrying a substantial clinical and preclinical literature. Phenibut’s distinguishing features are a different pharmacokinetic profile (5-6 hour half-life, rapid oral absorption) and its long history in Soviet and post-Soviet clinical practice across Russia, Belarus, Kazakhstan, and Latvia. But “different from baclofen” is a weak differentiator when baclofen is already the better-studied probe for the same receptor system. Some voltage-gated calcium channel activity shows up at higher concentrations, which is mildly interesting mechanistically, but it doesn’t reframe what this compound is doing.

The evidence base is real but messy. Decades of Russian-language clinical literature document use for anxiety, insomnia, and asthenia, and the compound is approved in multiple countries, which means at least some regulatory body looked at the data. Western replication is essentially absent, though. Russian clinical trials from that era are difficult to evaluate on methodological grounds, and thats not a criticism of the underlying science so much as an honest accounting of what investigators here can actually work with. No phase 2 or 3 Western RCTs. No multi-center replicated trials in English-language literature that hold up to modern scrutiny.

What we dont like: the dependence liability is substantial and well-documented. Withdrawal resembling benzodiazepine or baclofen discontinuation syndrome has been reported with chronic high-dose use, and that’s not a minor footnote. It limits research utility considerably for anything beyond acute or intermittent dosing paradigms, and it adds IRB and ethics complications that better-characterized alternatives simply don’t carry. The US regulatory status as an increasingly scrutinized research chemical adds sourcing friction on top of that.

As a bench tool, phenibut retains some utility for GABA-B CNS pharmacology, particularly for investigators who need a probe with a different kinetic profile than baclofen or want to study the (R)-enantiomer selectivity question in stereoselective receptor work. There’s a narrow research niche here. But if you’re building a GABA-B program, baclofen is still the standard reference compound, and phenibut is supplementary at best.

This isn’t a compound we’d prioritize for a library oriented toward frontier targets. The mechanism is mature, the evidence base is murky by Western standards, and the dependence liability introduces real practical constraints that blunt its value as a routine research tool. The score reflects a real compound with a real pharmacological effect that just doesn’t offer much that’s new to a serious investigator in 2025.

Novelty

18

Mechanism promise

25

In-category differentiation

28

Evidence quality

38

Translational signal

42

Research bench value

32

Rationale Phenibut’s mechanism is a known quantity (GABA-B agonism, baclofen-adjacent) and the compound has been in Eastern European clinical use since the 1960s, producing a mature but methodologically limited evidence base with no Western RCTs. Dependence liability and US regulatory gray-zone status further constrain its utility as a serious research tool.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

GABA-B agonist / phenyl-GABA

A Soviet-developed phenyl-substituted GABA analog with GABA-B receptor agonism, used clinically in Russia for anxiety and sleep with documented dependence liability.

Abstract

Phenibut (4-amino-3-phenyl-butanoic acid; CAS 1078-21-3; molecular formula C10H13NO2; molecular weight 179.22) is a phenyl-substituted GABA analog developed in the Soviet Union in the 1960s at the Herzen State Pedagogical University. The phenyl substitution at the 3-position confers blood-brain barrier permeability that GABA itself lacks. Phenibut is approved in Russia, Belarus, Kazakhstan, and Latvia as Phenibut, Noofen, and Anvifen for anxiety, insomnia, asthenia, and post-traumatic stress disorder. Mechanism is primarily GABA-B receptor agonism (similar to baclofen) with secondary effects on voltage-gated calcium channels at higher doses. The (R)-enantiomer is the active component. Pharmacokinetics: plasma half-life 5 to 6 hours; rapid oral absorption. Doses are 250 to 1500 mg per day. Phenibut has documented dependence liability with chronic high-dose use; withdrawal syndrome includes anxiety, insomnia, tremor, and rebound symptoms. The compound is sold as a research chemical/dietary supplement in the United States though regulatory classification is increasingly restrictive in some states. Investigators should be aware of the dependence potential and avoid daily dosing schedules.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-067Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Retatrutide

Plain-language summaryIntrigue 91 / 100

Retatrutide is a triple agonist activating GLP-1, GIP, and glucagon receptors simultaneously. The glucagon component adds a fat-burning effect on top of the appetite suppression and glucose control of GLP-1/GIP. Phase 3 trials are ongoing for obesity. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNovel frontier

82/100

Triple GIP/GLP-1/glucagon agonist with extraordinary Phase 2 weight-loss signal, currently the frontier of metabolic peptide research

Look, the GLP-1 era already redrew metabolic pharmacology, and tirzepatide added GIP to that picture. Retatrutide adds the third piece: glucagon receptor agonism. That’s not incremental. Stacking glucagon on top of dual incretin signaling gives you a compound that hits appetite through GLP-1, potentiates insulin dynamics through GIP, and drives hepatic energy expenditure and lipolytic output through glucagon. Three distinct pathways, one weekly injection. The pharmacological rationale is genuinely elegant.

The Jastreboff et al. Phase 2 trial, published in NEJM in 2023, showed 24.2 percent body weight reduction at 48 weeks in the highest-dose arm. That’s not a modest signal. Tirzepatide in SURMOUNT-1 topped out around 20.9 percent at 72 weeks. Retatrutide got further, faster. The dose-response curve is clean, the dropout rates manageable, and the effect on MASH markers adds another dimension the earlier incretins didn’t have. We’re not reading between the lines here, the Phase 2 data is unusually strong.

Mechanism-wise, the glucagon component deserves more attention than it usually gets in lay discussion. Glucagon receptor agonism in isolation would raise glucose, which sounds counterproductive. But in the context of GLP-1 and GIP coadministration, the hepatic energy expenditure and fat oxidation effects dominate while the hyperglycemic risk is substantially blunted. Its a balance thats been validated in rodent models and appears to hold in humans. Whether the hepatic effects specifically drive the MASH signal is still being worked out in ongoing arms of the trial.

What we like here is the research density. Retatrutide is useful as a probe for dissecting the incretin-glucagon axis in ways tirzepatide simply can’t address. You can ask questions about what glucagon receptor activation specifically contributes to metabolic outcomes by comparing the two compounds head-to-head in preclinical models. That’s real bench utility, not just clinical noise. The three-receptor design also opens questions about receptor crosstalk and downstream signaling that single or dual agonists leave on the table.

What we don’t like is the access picture. This is an investigational compound still in trials, not approved, not commercially available outside of study enrollment. Sourcing for preclinical work is achievable but not straightforward, and quality verification matters more here than with mature peptides. The long-term cardiovascular profile and the glucagon safety signal across diverse populations still need the Phase 3 readout to fully settle. But the Phase 2 results are the strongest weight-loss signal any injectable metabolic peptide has produced in a well-designed trial, and the mechanism has serious depth. For anyone working on incretin biology, metabolic regulation, or MASH models, retatrutide is the compound to watch right now.

Novelty

88

Mechanism promise

90

In-category differentiation

88

Evidence quality

68

Translational signal

80

Research bench value

68

Rationale Scores high across novelty, mechanism, and differentiation because adding glucagon receptor agonism to dual incretin pharmacology is genuinely new territory with strong pharmacological rationale, and Phase 2 human data showing 24.2% weight loss at 48 weeks is the strongest single-agent metabolic signal on record. Evidence score is moderated because Phase 3 is ongoing and regulatory status remains unconfirmed.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

GIP/GLP-1/glucagon triple receptor agonist

An Eli Lilly investigational triple receptor agonist of GIP, GLP-1, and glucagon receptors with Phase 3 trials in obesity producing 24% weight loss at 48 weeks.

Abstract

Retatrutide (LY3437943) is an investigational triple agonist of the GIP, GLP-1, and glucagon receptors developed by Eli Lilly and currently in Phase 3 trials for obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH). The compound builds on the GIP/GLP-1 dual agonist tirzepatide platform by adding glucagon receptor agonism, which contributes additional weight loss through hepatic energy expenditure increases and lipolytic effects. Phase 2 obesity trial results published in 2023 showed approximately 24.2 percent weight loss at 48 weeks at the highest dose, exceeding the magnitude observed with tirzepatide. The compound is not yet FDA approved; Phase 3 program is ongoing. Pharmacokinetics: weekly subcutaneous administration; half-life supports once-weekly dosing. The triple agonist class represents the current frontier of metabolic peptide development.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-084Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

←Previous Page

1 … 43 44 45 46 47 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.